

# 乳腺癌原发灶与复发转移灶中 ER、PR、HER-2 的表达变化

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年01期 页码: 64-66 栏目: 论著(胸部肿瘤) 出版日期: 2018-11-30

**Title:** Discordance of the expression of ER, PR and HER-2 between primary breast cancer and recurrent metastatic of breast cancer

**作者:** 田青青<sup>1</sup>; 刘立红<sup>1</sup>; 袁静萍<sup>2</sup>

1.华中科技大学同济医学院附属武汉市中心医院病理科, 湖北 武汉 430014; 2.武汉大学人民医院病理科, 湖北 武汉 430060

**Author(s):** Tian Qingqing<sup>1</sup>; Liu Lihong<sup>1</sup>; Yuan Jingping<sup>2</sup>

1.Department of Pathology, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Hubei Wuhan 430014, China; 2.Department of Pathology, Renmin Hospital of Wuhan University, Hubei Wuhan 430060, China.

**关键词:** 乳腺癌; 原发灶; 复发转移灶

**Keywords:** breast cancer; primary; recurrent metastatic

**分类号:** R737.9

**DOI:** 10.3969/j.issn.1672-4992.2019.01.016

**文献标识码:** A

**摘要:** 目的: 探讨乳腺癌原发灶与复发转移灶中雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(HER-2)的表达变化。方法: 采用免疫组化EnVision两步法检测68例乳腺癌原发灶与对应的复发转移灶中ER、PR、HER-2的表达。结果: ER、PR、HER-2在复发转移灶中的阳性率分别为26.47%、39.71%、33.82%, 较原发灶中(58.82%、55.88%、36.76%)明显降低。其中ER的变化有统计学差异( $P < 0.05$ ), PR、HER-2的变化无统计学差异( $P > 0.05$ )。结论: 乳腺癌复发转移灶中ER、PR、HER-2的表达均降低。对于复发转移的乳腺癌患者应重新检测ER、PR、HER-2。

**Abstract:** Objective: To investigate discordance of ER, PR and HER-2 between primary and recurrent metastatic of breast cancer. Methods: ER, PR and HER-2 expression in 68 cases with primary breast cancer and the corresponding recurrent metastatic cancer were detected by immunohistochemical EnVision method. Results: The positive rates of ER, PR and HER-2 in recurrent metastatic cancer were 26.47%, 39.71%, 33.82%, obviously reduced compared with primary 58.82%, 55.88%, 36.76%. The difference of ER was statistically significant ( $P < 0.05$ ), while the difference of PR and HER-2 was not significant ( $P > 0.05$ ). Conclusion: The expression of ER, PR and HER-2 in recurrent metastatic breast cancer was obviously reduced than those in primary. ER, PR, HER-2 should be retested for recurrent metastatic breast cancer patients.

## 参考文献/REFERENCES

- [1] Harbeck N, Gnant M. Breast cancer [J]. Lancet, 2017, 389(10074): 1134-1150.
- [2] Zhang BL, Song FJ. Genomics of breast cancer [J]. Chin J Clin Oncol, 2014, 41(3): 207-210. [张柏林, 宋丰举. 乳腺癌基因组学研究进展 [J]. 中国肿瘤临床, 2014, 41(3): 207-210.]
- [3] Breast Cancer HER2 Test Guide(2014) Writing Group. Breast Cancer HER2 Test Guide(2014) [J]. Chin J Pathol, 2014, 43(4): 262-267. [《乳腺癌HER2检测指南(2014版)》编写组. 乳腺癌HER2检测指南(2014版) [J]. 中华病理学杂志, 2014, 43(4): 262-267.]
- [4] Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol, 2010, 28(21): 2784-2795.
- [5] Chen CC, Xu PQ. Research progress of local recurrence after breast cancer surgery [J]. Chinese Journal of General Practice, 2013, 11(5): 770-771. [陈春春, 许培权. 乳腺癌术后局部复发研究进展 [J]. 中华全科医学, 2013, 11(5): 770-771.]
- [6] Deng Zhiping, Zhu Jiang, Ma Ningqiang, et al. Discordance of the expression of ER, PR and HER-2 receptor statuses between primary breast cancer and recurrent focuses [J]. Modern Oncology, 2011, 19(8): 1562-1564. [邓智平, 朱江, 马宁强, 等. 乳腺癌ER、PR、HER-2在原发灶及复发转移灶中表达变化 [J]. 现代肿瘤医

学, 2011, 19(8): 1562-1564.]

[7]Li WH, Zhang Y.Difference of ER, PR, HER-2, p53, Ki-67 expression in recurrence and/or metastasis compared to primary breast cancer [J] .J Clin Exp Pathol, 2016, 32(7): 727-730. [李文华, 张莹.乳腺癌复发转移灶与原发灶中ER、PR、HER-2、p53、Ki-67的表达差异 [J] .临床与实验病理学杂志, 2016, 32(7): 727-730.]

[8]Curtit E, Nerich V, Mansi L, et al.Discordances in estrogen receptor status, progesterone receptor status, and HER-2 status between primary breast cancer and metastasis [J] .Oncologist, 2013, 18(6): 667-674.

[9]Sun L, Yu DH, Sun SY, et al.Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers [J] .Cell Biochem Biophys, 2014, 68(3): 511-516.

[10] Broom RJ, Tang P.Changes in estrogen receptor(ER), progesteronereceptor(PR), and HER2/neu status with time.Discordancerates between primary and metastatic breast pathology samples [J] .Am Society Clin Oncol, 2007, 3(1): 45-48.

[11]Lower EE, Glass E.HER-2/neu expression in primary and metastatic breast cancer [J] .Breast Cancer Res Treat, 2009, 113(2): 301-306.

[12]Loibl S, Gianni L.HER-2-positive breast cancer [J] .Lancet, 2017, 389(10087): 2415-2429.

[13]Denkert C, Liedtke C, Tutt A, et al.Molecular alterations in triple-negative breast cancer-the road to new treatment strategies [J] .Lancet, 2017, 389(10087): 2430-2442.

---

**备注/Memo:** 武汉市科技计划项目 (编号: 2017060201010172)

---

更新日期/Last Update: 2018-11-30